Literature DB >> 26849483

Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom.

Meryl Brod1, Kathryn M Pfeiffer1, Anthony H Barnett2, Kerstin Berntorp3, Tina Vilsbøll4, Benno Weissenberger5.   

Abstract

Objective A large proportion of people with type 2 diabetes (T2D) remain uncontrolled on basal insulin. Yet, there is limited understanding of how people with uncontrolled type 2 diabetes (PWUD) perceive control and insulin intensification and whether their perceptions differ from those of physicians. The purpose of the study was to investigate perceptions of control and views on insulin intensification among physicians and PWUD. Research design and methods Web surveys of 1012 PWUD on basal insulin and 300 physicians were conducted in Sweden, Switzerland, and the United Kingdom. Results Analyses revealed significant differences between physicians and PWUD. Physicians were significantly more likely than PWUD to indicate that HbA1c (85.0% vs. 78.9%, p < 0.05), complications from diabetes (89.3% vs. 75.3%, p < 0.001), and frequency/severity of hypoglycemia (93.3% vs. 68.6%, p < 0.001) were very/extremely important for deciding whether or not diabetes is well controlled. In contrast PWUD were significantly more likely to place importance on a variety of factors, including energy levels (74.5% vs. 33.0%, p < 0.001), insulin units/day (77.6% vs. 29.0%, p < 0.001) and how predictable life is (72.1% vs. 29.3%, p < 0.001). PWUD also perceived significantly greater obstacles to control and viewed uncontrolled T2D as more interfering in their lives compared to physicians. Physicians were most reluctant to intensify insulin when there is a lack of patient agreement. Worries about weight gain and feelings of 'getting sicker' were the most frequently reported reasons why PWUD on basal insulin were reluctant to intensify insulin. Conclusions Results revealed a significant disconnect between physicians and PWUD in their perceptions of diabetes control. While physicians generally expressed a more focused and clinical view of diabetes control, patients had a broader view. Results also provide insights into PWUD and physicians' reluctance to intensify insulin. The findings suggest that physician and patient education on differing perceptions could benefit communication and improve diabetes management.

Entities:  

Keywords:  Diabetes control; Diabetes management; Insulin intensification; Perceptions of control

Mesh:

Substances:

Year:  2016        PMID: 26849483     DOI: 10.1185/03007995.2016.1150821

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Clinical Use of IDegLira: Initiation to Titration After Basal Insulin.

Authors:  Mark Warren; Donna Steel
Journal:  Clin Diabetes       Date:  2020-01

2.  Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

Authors:  Vanita R Aroda; Joseph R Arulandu; Anthony J Cannon
Journal:  Clin Diabetes       Date:  2018-04

3.  Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study.

Authors:  Kenneth J Tomaszewski; Amy Allen; Michelle Mocarski; Alisa Schiffman; Davida Kruger; Yehuda Handelsman; Michael Heile; Meryl Brod
Journal:  Patient Prefer Adherence       Date:  2019-05-10       Impact factor: 2.711

4.  Do Weight trajectories influence diabetes control? A prospective study in Switzerland (CoLaus study).

Authors:  Pauline Ducraux; Gérard Waeber; Pedro Marques-Vidal
Journal:  Prev Med Rep       Date:  2021-06-27

5.  Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland.

Authors:  Peter Wiesli; Marcus Schories
Journal:  Diabetes Ther       Date:  2018-10-09       Impact factor: 2.945

6.  IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.

Authors:  Eden Miller; Ankur Doshi; Randi Grøn; Esteban Jódar; Petra Őrsy; Mattis F Ranthe; Danny Sugimoto; Nikolaos Tentolouris; Adie Viljoen; Liana K Billings
Journal:  Diabetes Obes Metab       Date:  2019-08-28       Impact factor: 6.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.